Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel Free NMTR Stock Alerts

9 Meters Biopharma (NMTR) Competitors

9 Meters Biopharma logo
Compare

NMTR vs. CVKD, SBFM, REVB, SXTP, and XRTX

Should you buy 9 Meters Biopharma stock or one of its competitors? 9 Meters Biopharma's main competitors and comparable companies include Cadrenal Therapeutics (CVKD), Sunshine Biopharma (SBFM), Revelation Biosciences (REVB), 60 Degrees Pharmaceuticals (SXTP), and XORTX Therapeutics (XRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 9 Meters Biopharma compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for 9 Meters Biopharma. Cadrenal Therapeutics' average media sentiment score of 1.14 beat 9 Meters Biopharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cadrenal Therapeutics Positive
9 Meters Biopharma Neutral

Cadrenal Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Cadrenal Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 1,060.71%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadrenal TherapeuticsN/AN/A-$13.24M-$4.90N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Cadrenal Therapeutics' return on equity of -406.41% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cadrenal TherapeuticsN/A -406.41% -273.80%
9 Meters Biopharma N/A -584.97%-159.45%

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cadrenal Therapeutics beats 9 Meters Biopharma on 9 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Sunshine Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Sunshine Biopharma currently has a consensus price target of $70.00, suggesting a potential upside of 8,458.50%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Sunshine Biopharma is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunshine Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sunshine Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

9 Meters Biopharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sunshine Biopharma-17.94% -26.36% -20.60%
9 Meters Biopharma N/A -584.97%-159.45%

Sunshine Biopharma has higher revenue and earnings than 9 Meters Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunshine Biopharma$36.31M0.10-$5.97M-$10.15N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, Sunshine Biopharma had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for 9 Meters Biopharma. Sunshine Biopharma's average media sentiment score of 0.97 beat 9 Meters Biopharma's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Sunshine Biopharma Positive
9 Meters Biopharma Neutral

Summary

Sunshine Biopharma beats 9 Meters Biopharma on 10 of the 15 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

In the previous week, Revelation Biosciences had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Revelation Biosciences and 0 mentions for 9 Meters Biopharma. Revelation Biosciences' average media sentiment score of 1.41 beat 9 Meters Biopharma's score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Revelation Biosciences Positive
9 Meters Biopharma Neutral

Revelation Biosciences' return on equity of -100.19% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -100.19% -82.72%
9 Meters Biopharma N/A -584.97%-159.45%

Revelation Biosciences is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$12.31N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Revelation Biosciences has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Summary

Revelation Biosciences beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

60 Degrees Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M3.12-$7.36M-$4.82N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for 9 Meters Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 1.33 beat 9 Meters Biopharma's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
9 Meters Biopharma Neutral

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

9 Meters Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-650.21% N/A -136.81%
9 Meters Biopharma N/A -584.97%-159.45%

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 1,008.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

60 Degrees Pharmaceuticals beats 9 Meters Biopharma on 10 of the 15 factors compared between the two stocks.

How does 9 Meters Biopharma compare to XORTX Therapeutics?

XORTX Therapeutics (NASDAQ:XRTX) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, XORTX Therapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for XORTX Therapeutics and 0 mentions for 9 Meters Biopharma. XORTX Therapeutics' average media sentiment score of 0.39 beat 9 Meters Biopharma's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
XORTX Therapeutics Neutral
9 Meters Biopharma Neutral

XORTX Therapeutics' return on equity of -137.85% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -137.85% -108.16%
9 Meters Biopharma N/A -584.97%-159.45%

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than XORTX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

XORTX Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Summary

XORTX Therapeutics beats 9 Meters Biopharma on 8 of the 12 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTR vs. The Competition

Export
Metric9 Meters BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.04M$12.66B$7.34B$13.18B
Dividend YieldN/A2.62%2.52%14.03%
P/E Ratio0.00792.36274.7625.59
Price / SalesN/A758.21613.3683.42
Price / CashN/A15.2228.0235.00
Price / BookN/A10.6310.536.44
Net Income-$43.77M$2.84B$3.50B$360.47M

9 Meters Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
CVKD
Cadrenal Therapeutics
3.0814 of 5 stars		$1.20
-9.1%		$13.00
+983.3%		-91.8%$4MN/AN/A5
SBFM
Sunshine Biopharma
3.5875 of 5 stars		$0.80
-8.6%		$70.00
+8,648.9%		-94.2%$3.91M$36.31MN/A50
REVB
Revelation Biosciences
1.3909 of 5 stars		$0.87
-6.9%		N/A-84.8%$3.90MN/AN/A9
SXTP
60 Degrees Pharmaceuticals
2.4766 of 5 stars		$1.15
-0.9%		$13.85
+1,104.3%		-78.5%$3.66M$1.41MN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 9/28/2026 by MarketBeat.com Staff.
From Our Partners
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Dec 8th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
This AI Stock Reminds One Analyst of Early Nvidia
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel